Skip to main content
Erschienen in: Virchows Archiv 1/2012

01.01.2012 | Original Article

Expression of Raf-1 kinase inhibitory protein in carcinoma of the ampulla of Vater

verfasst von: Hyun-Soo Kim, Sun Ho Lee, Kyu Yeoun Won, Gou Young Kim, Yong-Koo Park, Youn Wha Kim

Erschienen in: Virchows Archiv | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of human malignancies. We have recently demonstrated that reduced expression of RKIP is significantly associated with invasion and metastasis in periampullary carcinomas, including pancreatic carcinoma, gallbladder carcinoma, and extrahepatic bile duct carcinoma. In this study, we evaluated RKIP expression in ampulla of Vater (AoV) carcinoma and investigated its prognostic significance. Immunostaining for RKIP was performed for 80 and 21 cases with primary and nodal metastatic AoV carcinoma, respectively. RKIP expression was reduced in 32.5% (26/80) and 66.7% (14/21) of primary and nodal metastatic AoV carcinoma cases, respectively. This distribution of RKIP expression was statistically significant (P < 0.001). The reduction in RKIP expression was significantly associated with the presence of nodal (P = 0.008) and distant (P = 0.002) metastases, a higher TNM stage group (P = 0.010), lymphatic invasion (P < 0.001), vascular invasion (P < 0.001), and a shorter disease-free survival (DFS; P = 0.028) and distant metastasis-free survival (DMFS; P = 0.005). In addition, reduced RKIP expression was an independent prognostic predictor for worse DFS and DMFS (P = 0.032 and P = 0.036, respectively). Our data suggest that a reduction in RKIP expression contributes to invasion and metastasis in AoV carcinoma and is a significant prognostic marker in patients with AoV carcinoma.
Literatur
1.
Zurück zum Zitat Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401:173–177PubMedCrossRef Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401:173–177PubMedCrossRef
2.
Zurück zum Zitat Park S, Yeung ML, Beach S, Shields JM, Yeung KC (2005) RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24:3535–3540PubMedCrossRef Park S, Yeung ML, Beach S, Shields JM, Yeung KC (2005) RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24:3535–3540PubMedCrossRef
3.
Zurück zum Zitat Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B (2004) Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 91:169–200PubMedCrossRef Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B (2004) Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 91:169–200PubMedCrossRef
4.
Zurück zum Zitat Kroslak T, Koch T, Kahl E, Hollt V (2001) Human phosphatidylethanolamine-binding protein facilitates heterotrimeric G protein-dependent signaling. J Biol Chem 276:39772–39778PubMedCrossRef Kroslak T, Koch T, Kahl E, Hollt V (2001) Human phosphatidylethanolamine-binding protein facilitates heterotrimeric G protein-dependent signaling. J Biol Chem 276:39772–39778PubMedCrossRef
5.
Zurück zum Zitat Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM (2001) Raf kinase inhibitor protein interacts with NF–kappaB-inducing kinase and TAK1 and inhibits NF–kappaB activation. Mol Cell Biol 21:7207–7217PubMedCrossRef Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM (2001) Raf kinase inhibitor protein interacts with NF–kappaB-inducing kinase and TAK1 and inhibits NF–kappaB activation. Mol Cell Biol 21:7207–7217PubMedCrossRef
6.
Zurück zum Zitat Lorenz K, Lohse MJ, Quitterer U (2003) Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426:574–579PubMedCrossRef Lorenz K, Lohse MJ, Quitterer U (2003) Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426:574–579PubMedCrossRef
7.
Zurück zum Zitat Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, Garcia JJ, Scott L, Fyfe N, Murray GI, Kolch W (2006) Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 24:5672–5679PubMedCrossRef Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, Garcia JJ, Scott L, Fyfe N, Murray GI, Kolch W (2006) Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 24:5672–5679PubMedCrossRef
8.
Zurück zum Zitat Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR, Lugli A (2007) Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol 127:820–827PubMedCrossRef Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR, Lugli A (2007) Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol 127:820–827PubMedCrossRef
9.
Zurück zum Zitat Chatterjee D, Sabo E, Tavares R, Resnick MB (2008) Inverse association between Raf kinase inhibitory protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res 14:2994–3001PubMedCrossRef Chatterjee D, Sabo E, Tavares R, Resnick MB (2008) Inverse association between Raf kinase inhibitory protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res 14:2994–3001PubMedCrossRef
10.
Zurück zum Zitat Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, Garcia JJ, Kolch W (2005) Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 11:7392–7397PubMedCrossRef Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, Garcia JJ, Kolch W (2005) Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 11:7392–7397PubMedCrossRef
11.
Zurück zum Zitat Chen Y, Ouyang GL, Yi H, Li MY, Zhang PF, Li C, Li JL, Liu YF, Chen ZC, Xiao ZQ (2008) Identification of RKIP as an invasion suppressor protein in nasopharyngeal carcinoma by proteomic analysis. J Proteome Res 7:5254–5262PubMedCrossRef Chen Y, Ouyang GL, Yi H, Li MY, Zhang PF, Li C, Li JL, Liu YF, Chen ZC, Xiao ZQ (2008) Identification of RKIP as an invasion suppressor protein in nasopharyngeal carcinoma by proteomic analysis. J Proteome Res 7:5254–5262PubMedCrossRef
12.
Zurück zum Zitat Li HZ, Wang Y, Gao Y, Shao J, Zhao XL, Deng WM, Liu YX, Yang J, Yao Z (2008) Effects of Raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 6:917–928PubMedCrossRef Li HZ, Wang Y, Gao Y, Shao J, Zhao XL, Deng WM, Liu YX, Yang J, Yao Z (2008) Effects of Raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 6:917–928PubMedCrossRef
13.
Zurück zum Zitat Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK (2004) Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64:5186–5192PubMedCrossRef Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK (2004) Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64:5186–5192PubMedCrossRef
14.
Zurück zum Zitat Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95:878–889PubMedCrossRef Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95:878–889PubMedCrossRef
15.
Zurück zum Zitat Brennan M (1995) Surgical management of peripancreatic cancer. In: Bland KI, Karakousis CP, Copeland EM (eds) Atlas of surgical oncology. W. B. Saunders Company, Philadelphia, pp 473–485 Brennan M (1995) Surgical management of peripancreatic cancer. In: Bland KI, Karakousis CP, Copeland EM (eds) Atlas of surgical oncology. W. B. Saunders Company, Philadelphia, pp 473–485
16.
Zurück zum Zitat Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB (2001) Periampullary cancers: are there differences? Surg Clin North Am 81:543–555PubMedCrossRef Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB (2001) Periampullary cancers: are there differences? Surg Clin North Am 81:543–555PubMedCrossRef
17.
Zurück zum Zitat Kim HS, Kim GY, Lim SJ, Kim YW (2010) Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology 42:655–660PubMedCrossRef Kim HS, Kim GY, Lim SJ, Kim YW (2010) Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology 42:655–660PubMedCrossRef
18.
Zurück zum Zitat Kim HS, Kim GY, Lim SJ, Park YK, Kim YW (2010) Reduced expression of Raf-1 kinase inhibitory protein is a significant prognostic marker in patients with gallbladder carcinoma. Hum Pathol 41:1609–1616PubMedCrossRef Kim HS, Kim GY, Lim SJ, Park YK, Kim YW (2010) Reduced expression of Raf-1 kinase inhibitory protein is a significant prognostic marker in patients with gallbladder carcinoma. Hum Pathol 41:1609–1616PubMedCrossRef
19.
Zurück zum Zitat Kim HS, Kim GY, Lim SJ, Kim YW (2010) Expression of Raf-1 kinase inhibitory protein in extrahepatic bile duct carcinoma. Korean J Pathol 44:234–242CrossRef Kim HS, Kim GY, Lim SJ, Kim YW (2010) Expression of Raf-1 kinase inhibitory protein in extrahepatic bile duct carcinoma. Korean J Pathol 44:234–242CrossRef
20.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer staging manual, 7th edn. Springer, New York Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer staging manual, 7th edn. Springer, New York
21.
Zurück zum Zitat Kim HS, Kim GY, Lim SJ, Kim YW (2010) Raf-1 kinase inhibitory protein expression in thyroid carcinomas. Endocr Pathol 21:253–257PubMedCrossRef Kim HS, Kim GY, Lim SJ, Kim YW (2010) Raf-1 kinase inhibitory protein expression in thyroid carcinomas. Endocr Pathol 21:253–257PubMedCrossRef
22.
Zurück zum Zitat Al-Mulla F, Hagan S, Al-Ali W, Jacob SP, Behbehani AI, Bitar MS, Dallol A, Kolch W (2008) Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J Clin Pathol 61:524–529PubMedCrossRef Al-Mulla F, Hagan S, Al-Ali W, Jacob SP, Behbehani AI, Bitar MS, Dallol A, Kolch W (2008) Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J Clin Pathol 61:524–529PubMedCrossRef
23.
Zurück zum Zitat Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET (2006) Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 66:248–256PubMedCrossRef Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET (2006) Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 66:248–256PubMedCrossRef
24.
Zurück zum Zitat Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z (2009) Effects of Raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res 7:832–840PubMedCrossRef Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, Yao Z (2009) Effects of Raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res 7:832–840PubMedCrossRef
25.
Zurück zum Zitat Kim SH, Kim HJ, Park YN, Cho SH (2001) The expression of extracellular signal regulated kinase (ERK) in non-small cell lung carcinoma. Korean J Pathol 35:361–367 Kim SH, Kim HJ, Park YN, Cho SH (2001) The expression of extracellular signal regulated kinase (ERK) in non-small cell lung carcinoma. Korean J Pathol 35:361–367
26.
Zurück zum Zitat Lee HC, Tian B, Sedivy JM, Wands JR, Kim M (2006) Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 131:1208–1217PubMedCrossRef Lee HC, Tian B, Sedivy JM, Wands JR, Kim M (2006) Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 131:1208–1217PubMedCrossRef
27.
Zurück zum Zitat Wang J, Yang YH, Wang AQ, Yao B, Xie G, Feng G, Zhang Y, Cheng ZS, Hui L, Dai TZ, Du XB, Wang D (2010) Immunohistochemical detection of the Raf kinase inhibitor protein in nonneoplastic gastric tissue and gastric cancer tissue. Med Oncol 27:219–223PubMedCrossRef Wang J, Yang YH, Wang AQ, Yao B, Xie G, Feng G, Zhang Y, Cheng ZS, Hui L, Dai TZ, Du XB, Wang D (2010) Immunohistochemical detection of the Raf kinase inhibitor protein in nonneoplastic gastric tissue and gastric cancer tissue. Med Oncol 27:219–223PubMedCrossRef
28.
Zurück zum Zitat Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813–822PubMedCrossRef Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813–822PubMedCrossRef
29.
Zurück zum Zitat Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA (1997) Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137:481–492PubMedCrossRef Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA (1997) Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 137:481–492PubMedCrossRef
30.
Zurück zum Zitat Kajanne R, Miettinen P, Mehlem A, Leivonen SK, Birrer M, Foschi M, Kahari VM, Leppa S (2007) EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol 212:489–497PubMedCrossRef Kajanne R, Miettinen P, Mehlem A, Leivonen SK, Birrer M, Foschi M, Kahari VM, Leppa S (2007) EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol 212:489–497PubMedCrossRef
31.
Zurück zum Zitat McCawley LJ, Li S, Wattenberg EV, Hudson LG (1999) Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 274:4347–4353PubMedCrossRef McCawley LJ, Li S, Wattenberg EV, Hudson LG (1999) Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 274:4347–4353PubMedCrossRef
32.
Zurück zum Zitat Peraldi P, Frodin M, Barnier JV, Calleja V, Scimeca JC, Filloux C, Calothy G, Van Obberghen E (1995) Regulation of the MAP kinase cascade in PC12 cells: B-Raf activates MEK-1 (MAP kinase or ERK kinase) and is inhibited by cAMP. FEBS Lett 357:290–296PubMedCrossRef Peraldi P, Frodin M, Barnier JV, Calleja V, Scimeca JC, Filloux C, Calothy G, Van Obberghen E (1995) Regulation of the MAP kinase cascade in PC12 cells: B-Raf activates MEK-1 (MAP kinase or ERK kinase) and is inhibited by cAMP. FEBS Lett 357:290–296PubMedCrossRef
33.
Zurück zum Zitat Trakul N, Menard RE, Schade GR, Qian Z, Rosner MR (2005) Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation. J Biol Chem 280:24931–24940PubMedCrossRef Trakul N, Menard RE, Schade GR, Qian Z, Rosner MR (2005) Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation. J Biol Chem 280:24931–24940PubMedCrossRef
34.
Zurück zum Zitat Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S (2005) Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 106:3423–3431PubMedCrossRef Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S (2005) Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 106:3423–3431PubMedCrossRef
Metadaten
Titel
Expression of Raf-1 kinase inhibitory protein in carcinoma of the ampulla of Vater
verfasst von
Hyun-Soo Kim
Sun Ho Lee
Kyu Yeoun Won
Gou Young Kim
Yong-Koo Park
Youn Wha Kim
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 1/2012
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-011-1174-y

Weitere Artikel der Ausgabe 1/2012

Virchows Archiv 1/2012 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …